Voyager Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de Voyager Therapeutics disminuyan a un ritmo anual de 12% y 29.4% respectivamente, mientras que se espera que el BPA disminuya un 20.5% por año.

Información clave

-29.4%

Tasa de crecimiento de los beneficios

-20.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	-12.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	14 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09

Recent updates

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Nov 18

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Oct 17

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Aug 26

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Aug 08

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

May 12

Voyager Does A Reboot After First Generation Failures

Mar 25

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:VYGR - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	69	-107	-60	-55	7
12/31/2025	60	-111	-105	-103	10
12/31/2024	90	-53	-29	-25	8
9/30/2024	164	26	-29	-25	N/A
6/30/2024	144	9	-22	-18	N/A
3/31/2024	119	-3	8	13	N/A
12/31/2023	250	132	75	78	N/A
9/30/2023	158	52	86	89	N/A
6/30/2023	195	96	91	94	N/A
3/31/2023	191	99	74	77	N/A
12/31/2022	41	-46	-15	-13	N/A
9/30/2022	71	-17	9	11	N/A
6/30/2022	31	-60	4	6	N/A
3/31/2022	32	-71	1	2	N/A
12/31/2021	37	-71	-55	-54	N/A
9/30/2021	16	-93	-92	-87	N/A
6/30/2021	132	18	-100	-91	N/A
3/31/2021	160	39	-100	-89	N/A
12/31/2020	171	37	-109	-97	N/A
9/30/2020	197	40	-110	-98	N/A
6/30/2020	100	-61	-103	-95	N/A
3/31/2020	117	-41	-113	-105	N/A
12/31/2019	104	-44	41	49	N/A
9/30/2019	74	-54	43	48	N/A
6/30/2019	55	-59	47	52	N/A
3/31/2019	12	-96	57	61	N/A
12/31/2018	8	-88	-20	-16	N/A
9/30/2018	12	-78	-10	-6	N/A
6/30/2018	11	-81	N/A	-5	N/A
3/31/2018	10	-74	N/A	2	N/A
12/31/2017	10	-71	N/A	-61	N/A
9/30/2017	6	-74	N/A	-60	N/A
6/30/2017	8	-59	N/A	-54	N/A
3/31/2017	11	-50	N/A	-47	N/A
12/31/2016	14	-40	N/A	-42	N/A
9/30/2016	17	-34	N/A	-39	N/A
6/30/2016	18	-32	N/A	-36	N/A
3/31/2016	20	-30	N/A	-33	N/A
12/31/2015	17	-38	N/A	41	N/A
9/30/2015	12	-35	N/A	46	N/A
6/30/2015	7	-32	N/A	50	N/A
3/31/2015	3	-30	N/A	55	N/A
12/31/2014	N/A	-18	N/A	-12	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de VYGR disminuyan en los próximos 3 años (-29.4% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de VYGR disminuyan en los próximos 3 años (-29.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de VYGR disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de VYGR disminuyan en los próximos 3 años (-12% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de VYGR disminuyan en los próximos 3 años (-12% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VYGR se prevé que sea elevada dentro de 3 años.

Voyager Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 42%

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Consensus revenue estimates increase by 29%

Consensus revenue estimates fall by 21%

Price target increased by 9.8% to US$11.17

Price target increased to US$8.20

Recent updates

Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026

Investor sentiment deteriorates as stock falls 23%

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Investor sentiment deteriorates as stock falls 19%

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Investor sentiment improves as stock rises 20%

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Consensus revenue estimates increase by 42%

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Consensus revenue estimates increase by 29%

Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold US$119k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Consensus revenue estimates fall by 21%

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Investor sentiment improves as stock rises 18%

President recently sold US$97k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New minor risk - Share price stability

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold US$95k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Chief Science Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 25%

Price target increased by 9.8% to US$11.17

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President recently sold US$58k worth of stock

Chief Operating Officer recently sold US$126k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$8.20

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Consensus revenue estimates increase by 170%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target